Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment (NCT02583906) | Clinical Trial Compass
TerminatedNot Applicable
Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment
Stopped: Not enough participants
Belgium8 participantsStarted 2014-04
Plain-language summary
Evaluation of the effect of CPAP (continuous positive airway pressure ) treatment in PAH (pulmonary arterial hypertension) and CTEPH (chronic thromboembolic pulmonary hypertension) patients suffering from sleep disordered breathing.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* minimum 18 years old
* diagnosed with PAH or non-operable CTEPH or operated CTEPH with peristent pulmonary hypertension
* diagnosis of PAH based on cardiac catherisation
* diagnosis of CTEPH confirmed by contrast-enhanced spiral chest CT, pulmonary angiography and V/Q scintigraphy
* recent diagnosis of sleep disordered breathing (polysomnography realized within 3 months before inclusion showing AHI above 15) stable clinical condition for at least 3 months before inclusion as defined by NYHA and a walking distance difference within 10% of the previous 3 months and no change in medical therapy during this 3 months
Exclusion Criteria:
* congenital heart disease
* moderate and severe restrictive or obstructive pulmonary disease with a TLC and a FEV1\<60% of the predicted value
* BMI 35kg/m2 or more
* patients already treated with CPAP
* patients with severe sleepiness (epworth sleepiness scale from 18 to 24/24)
What they're measuring
1
Change in PVR (pulmonary vascular resistance)
Timeframe: change in PVR from inclusion at 6 months